

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1805
Examiner: Mr. David Guzo

#35
WJH
6/25/97

In re PATENT APPLICATION of:

Applicant(s) : WILSON et al.

Application No.: 08/302,241

Filed : September 8, 1994

For : RECOMBINANT DNA SEQUENCES,
VECTORS CONTAINING THEM
AND METHOD FOR THE USE
THEREOF

TERMINAL
DISCLAIMER

Attorney Docket: CARPR 0022C2

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Celltech Limited, located at 216 Bath Road, Slough,
Berkshire SL2 4EN, England, a British Company, and The
University Court of the University of Glasgow, located at 502
University Court of the University of Glasgow, The University
Avenue, Glasgow, G12 8QQ, Glasgow, Scotland, a corporation of
Great Britain, assignees of the entire right, title and
interest in the above-identified application by virtue of an
Assignment recorded at the United States Patent and Trademark
at Reel 4790, Frame 0784, on October 22, 1987, hereby
disclaims except as provided below the terminal part of the
statutory term of any patent granted on the above-identified
application, which would extend beyond the expiration date of
the earlier of the full statutory term defined in 35 U.S.C. §

06/26/1997 LCHALMER 00000064 DR#193700
01 FC:148 110.00 CH 08302241


154 and § 156 of the U.S. Patent No. 5,122,464 and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 5,122,464, and hereby agrees that any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the term defined in 35 U.S.C. § 154 in the event that U.S. Patent 5,122,464 expires for failure to pay a maintenance fee, is held unenforceable or is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise not deemed to provide the rights conveyed by 35 U.S.C. § 154 prior to the expiration of its full statutory term, except for the separation of legal title stated above.

The undersigned is the assignee of the above patent application by virtue of an assignment recorded in the United States Patent and Trademark Office on October 22, 1987 at Reel 4790, Frame 0784. The assignment has been reviewed and it is certified that, to the best of the knowledge and belief


of the assignee, acting through the undersigned, title is in the assignee.

Done this 4TH day of DECEMBER, 1996 by the undersigned officer of CELLTECH THERAPEUTICS LIMITED (formerly known as CELLTECH LIMITED) and THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW both duly authorized to act for the assignee under the laws of the United Kingdom.

By  X

Name: David Philip Bloxham

Title: Chief Executive

By 

Name: DUGALD MACKIE

Title: SECRETARY OF COURT